Join Tao Pan, PhD, for a presentation on key advances in functional genomics, exploring snoRNAs, tRNA modifications, and how dynamic translation regulates cancer growth and tumor-microbiome crosstalk.
#Epitranscriptomics #Genomics #CancerResearch
https://biophysics.uchicago.edu/the-faculty/tao_pan/

A new phase II/III trial results published in Journal of Clinical Oncology, demonstrating improved PFS in patients with low/absent pretreatment CTCs, but not in oligometastatic condition with metastasis-directed ablation. @uchicagomedicine.bsky.social
https://ascopubs.org/doi/10.1200/JCO-26-00201

A new phase II/III trial results published in the Journal of Clinical Oncology demonstrating improved PFS in patients with low/absent pretreatment CTCs, but not in oligometastatic condition with metastasis-directed ablation. @UChicagoMed @UChicagoBreast
https://ascopubs.org/doi/10.1200/JCO-26-00201

🔥Hot off the press: Researchers at the University of Chicago in collaboration with Fred Hutch discovered that low levels of tRNAArg (UCU)-1 drive resistance to hormone receptor therapy in prostate cancer, paving the way for novel tRNA targeted therapies. Nature Portfolio
https://ow.ly/mkVk50ZVA0i

Diagnosed with stage 4 pancreatic cancer, Kerrie Watson had few options. Then, Dr. Ardaman Shergill enrolled her in a clinical trial for daraxonrasib—a novel targeted therapy. Today, she is living a normal life. #KRASinhibitors
@uchicagoobgyn.bsky.social
Read more: https://ow.ly/Blt550ZVtmP

Our team had a wonderful day at the American Cancer Society Making Strides Against Breast Cancer South Suburban walk in Orland Park, where UChicago Medicine was a sponsor. #BreastCancerAwarenessMonth #BCAM

WEBINAR ADDED!

Join Dr. Summer Hanson for an informative webinar exploring the full range of breast reconstruction options, and what to expect before, during, and after surgery. Details below.

Date: Tuesday, October 20th
Time: 12:00-1:00 PM CT
RSVP: https://bit.ly/4dSoJSD

A free, in-person HCC Lunch & Learn on October 24, 2026, at UChicago Medicine will provide critical education about liver health, liver disease, and hepatocellular carcinoma (HCC).
Learn more and register: www.bluefaery.org/hcc-lunch-le... #LiverCancer #CancerPrevention

October marks #BreastCancerAwarenessMonth!
The 5-year survival rate is nearly 100% when breast cancer is caught early. UChicago Medicine offers mammograms at 12 convenient locations. Don't wait, schedule your appointment today.
#EarlyDetectionSavesLives
https://ow.ly/X1oA50ZTzOr

Huge congratulations to Dr. Ernst Lengyel on receiving 2026 Lotus Award!🎉
This award will support Dr. Lengyel's research studying how metabolism reprogram ovarian cancer cells to unlock new targeted therapies.
#OvarianCancer
@uchicagomedicine.bsky.social
https://ow.ly/x9zV50ZT8uq

The new KRAS inhibitors look promising, but Dr. Ratain, and co-authors argue that oncology is still not doing enough to prove that patients are receiving the lowest effective dose with the fewest possible side effects.
University of Michigan @uchicagomedicine.bsky.social
https://ow.ly/y2zo50ZSMx1

October is #BreastCancerAwarenessMonth! Join us for a webinar series featuring University of Chicago Medicine faculty to discuss key topics in #breastcancer, including screening, prevention, & research!

#breastcancerawareness #breastcancerresearch #breastcancerprevention #breastcancerscreening

October is #BreastCancerAwarenessMonth! Join us for a webinar series featuring University of Chicago Medicine faculty to discuss key topics in #breastcancer, including screening, prevention, & research!

#breastcancerawareness #breastcancerresearch #breastcancerprevention #breastcancerscreening

A phase 1 trial led by Michael Bishop, MD, at UChicago Medicine and investigators at Mass General Brigham Cancer Institute, found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma.
https://ow.ly/agH950ZRalu

A phase 1 trial co-led by Michael Bishop, MD, at the UChicago MedIcine, found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma. #CAR-TTherapy #MultipleMyeloma #BCMATargeted
https://ow.ly/agH950ZRalu

🔥Hot off the press: Michael Bishop, MD, and colleagues report results from the phase 1 study of anito-cel, a BCMA-directed CAR T-cell therapy, showing encouraging activity in heavily pretreated relapsed/refractory multiple myeloma. NEJM.org @uchicagomedicine.bsky.social
https://ow.ly/itRY50ZR8qu

In a recent #SurvivorNet feature, Dr. Akash Patnaik, MD, PhD, highlights growing momentum in precision-based targeted therapies, immune-based approaches, and radioligand treatments such as FPI-2265 for advanced prostate cancer.
@uchicagomedicine.bsky.social
https://ow.ly/vnZO50ZR6Yq

On this #WorldCancerResearchDay, together with researchers, clinicians, patients, and partners, we remain committed to advancing knowledge, accelerating innovation, and improving cancer outcomes for all. #AdvancingCancerResearchTogether
@uchicagomedicine.bsky.social
https://ow.ly/4bq150ZQQaq

At a recent US Prostate Cancer Consensus Conference, Drs. Russell Szmulewitz and Rahul Aggarwal shared insights on the use of PARP inhibitor beyond BRCA2, and how to balance efficacy with long-term toxicity.
@uchicagomedicine.bsky.social
UCSF Health
Listen here: https://ow.ly/PNUp50ZQJZA